Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
1,071 articles
A newly discovered iron-MSRA pathway triggers the fat loss seen in cancer cachexia. Deleting MSRA in mice reduces wasting and prolongs survival.
A novel IL-21 cytokine mimic recruits CD4 T cells to make KRAS inhibition produce durable remissions in pancreatic cancer — a historically lethal disease.
CS18 targets a central cancer control hub, restoring drug sensitivity in resistant tumors and slowing growth in animal models.
PAI-1 fuels skin tumor growth via senescence, immunosuppression, and angiogenesis. A new inhibitor reverses anti-PD-1 resistance in melanoma.
A PAI-1 inhibitor forces quiescent leukemic stem cells out of dormancy, making them vulnerable to TKI therapy and potentially enabling treatment-free remission.
A new review reveals how PAI-1 fuels melanoma and other skin cancers by suppressing immunity, feeding tumor blood vessels, and blunting checkpoint inhibitor responses.
Amivantamab plus lazertinib significantly prolonged overall survival vs. osimertinib in Asian patients with EGFR-mutant advanced NSCLC.
Columbia scientists reprogrammed E. coli to produce chemotherapy and immune boosters inside solid tumors, triggering lasting systemic immunity in mice.
A 15-year Women's Health Initiative study shows chemotherapy and unhealthy lifestyles cause lasting physical decline in older breast cancer survivors.
A proteo-genomics approach maps cancer mutations to protein domains, revealing significance beyond gene-level or hotspot analysis.
A pioneering new breast cancer therapy wins FDA approval with a mechanism specifically engineered to prevent drug resistance from developing.
γδ T cells infiltrate small cell lung cancer tumors and retain tumor-killing ability, pointing to new immunotherapy strategies.
